Inhibitor Therapeutics' 10-K Reveals $3.3M Net Loss, $3.2M Negative Operating Cash Flow
Summary
Inhibitor Therapeutics reported a net loss of $3.3 million and negative operating cash flow of $3.2 million for the year ended December 31, 2025, as disclosed in its annual 10-K filing. These financial results are significant for a company with a market capitalization of approximately $15 million, indicating a substantial cash burn and continued reliance on external funding. While the company is progressing its lead oncology program and recently secured $3.0 million through a registered direct offering, the negative cash flow underscores ongoing financial pressures. Traders will be watching the company's burn rate closely and monitoring progress in its regulatory and formulation work to assess future financing requirements and potential clinical milestones.
At the time of this announcement, INTI was trading at $0.09 on OTC in the Life Sciences sector, with a market capitalization of approximately $15.1M. The 52-week trading range was $0.03 to $0.12. This news item was assessed with negative market sentiment and an importance score of 7 out of 10. Source: Wiseek News.